Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB

Molecular Psychiatry

Volumn 14, Issue 1, 2009, Pages 71-85

  Ribases M ^a   Ramos Quiroga, J A ^a,b   Hervas A ^c   Bosch, R ^a   Bielsa, A ^a   Gastaminza, X ^a   Artigas, J ^d   Rodriguez Ben, S ^c   Estivill, X ^e,f,g   Casas, M ^a,b   Cormand, B ^h,i   Bayes M ^e,f,g  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL MÚTUA DE TERRASSA   (Spain)

^d HOSPITAL DE SABADELL   (Spain)

^e CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^f Centro Nacional de Genotipado CeGen   (Spain)

^g CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

5HT2A; ADHD; Association study; DDC; MAOB; Serotonin

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CARBOXYLYASE; DIAMINOPIMELATE DECARBOXYLASE; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1E RECEPTOR; SEROTONIN 1F RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3A RECEPTOR; SEROTONIN 3B RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN 5A RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DNA MUTATIONAL ANALYSIS; DOPA DECARBOXYLASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MONOAMINE OXIDASE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN; YOUNG ADULT;

EID: 58049204451     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4002100     Document Type: Article

References (89)

1. Thapar A, O'Donovan M, Owen MJ. The genetics of attention deficit hyperactivity disorder. Hum Mol Genet 2005; 14: R275-R282.
2. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163: 716-723.
3. Faraone SV, Biederman J. What is the prevalence of adult ADHD? Results of a population screen of 966 adults. J Atten Disord 2005; 9: 384-391.
4. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366: 237-248.
5. Kessler RC, Adler LA, Barkley R, Biederman J, Conners CK, Faraone SV et al. Patterns and predictors of attention-deficit/ hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry 2005; 57: 1442-1451.
6. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000; 157: 816-818.
7. Weiss G. Followup studies on outcome of hyperactive children. Psychopharmacol Bull 1985; 21: 169-177.
8. Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 2006; 45: 192-202.
9. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA et al. Molecular genetics of attention-deficit/ hyperactivity disorder. Biol Psychiatry 2005; 57: 1313-1323.
10. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 2005; 57: 1215-1220.
11. Sprich S, Biederman J, Crawford MH, Mundy E, Faraone SV. Adoptive and biological families of children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2000; 39: 1432-1437.
12. Biederman J, Faraone SV, Mick E, Spencer T, Wilens T, Kiely K et al. High risk for attention deficit hyperactivity disorder among children of parents with childhood onset of the disorder: a pilot study. Am J Psychiatry 1995; 152: 431-435.
13. Biederman J, Faraone S, Milberger S, Curtis S, Chen L, Marrs A et al. Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1996; 35: 343-351.
14. Faraone SV, Biederman J, Monuteaux MC. Toward guidelines for pedigree selection in genetic studies of attention deficit hyperactivity disorder. Genet Epidemiol 2000; 18: 1-16.
15. Faraone SV, Biederman J, Feighner JA, Monuteaux MC. Assessing symptoms of attention deficit hyperactivity disorder in children and adults: which is more valid? J Consult Clin Psychol 2000; 68: 830-842.
16. Quist JF, Kennedy JL. Genetics of childhood disorders: XXIII. ADHD, Part 7: the serotonin system. J Am Acad Child Adolesc Psychiatry 2001; 40: 253-256.
17. Rapoport J, Quinn P, Scribanu N, Murphy DL. Platelet serotonin of hyperactive school age boys. Br J Psychiatry 1974; 125: 138-140.
18. Stoff DM, Pollock L, Vitiello B, Behar D, Bridger WH. Reduction of (3H)-imipramine binding sites on platelets of conduct-disordered children. Neuropsychopharmacology 1987; 1: 55-62.
19. Spivak B, Vered Y, Yoran-Hegesh R, Averbuch E, Mester R, Graf E et al. Circulatory levels of catecholamines, serotonin and lipids in attention deficit hyperactivity disorder. Acta Psychiatr Scand 1999; 99: 300-304.
20. Halperin JM, Newcorn JH, Schwartz ST, Sharma V, Siever LJ, Koda VH et al. Age-related changes in the association between serotonergic function and aggression in boys with ADHD. Biol Psychiatry 1997; 41: 682-689.
21. Castellanos FX, Elia J, Kruesi MJ, Gulotta CS, Mefford IN, Potter WZ et al. Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder. Psychiatry Res 1994; 52: 305-316.
22. Park SB, Coull JT, McShane RH, Young AH, Sahakian BJ, Robbins TW et al. Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. Neuropharmacology 1994; 33: 575-588.
23. Rubinstein S, Malone MA, Roberts W, Logan WJ. Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006; 16: 404-415.
24. Wilens TE, Biederman J, Spencer TJ. Attention deficit/hyperactivity disorder across the lifespan. Annu Rev Med 2002; 53: 113-131.
25. Popper CW. Antidepressants in the treatment of attention-deficit/ hyperactivity disorder. J Clin Psychiatry 1997; 58(Suppl 14): 14-29; discussion 30-1.
26. Malhotra S, Santosh PJ. An open clinical trial of buspirone in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1998; 37: 364-371.
27. Silverstone PH, Oldman D, Johnson B, Cowen PJ. Ondansetron, a 5-HT3 receptor antagonist, partially attenuates the effects of amphetamine: a pilot study in healthy volunteers. Int Clin Psychopharmacol 1992; 7: 37-43.
28. Layer RT, Uretsky NJ, Wallace LJ. Effect of serotonergic agonists in the nucleus accumbens on d-amphetamine-stimulated locomotion. Life Sci 1992; 50: 813-820.
29. McMahon LR, Cunningham KA. Antagonism of 5-hydroxytryptamine( 4) receptors attenuates hyperactivity induced by cocaine: putative role for 5-hydroxytryptamine(4) receptors in the nucleus accumbens shell. J Pharmacol Exp Ther 1999; 291: 300-307.
30. Ritz MC, Kuhar MJ. Relationship between self-administration of amphetamine and monoamine receptors in brain: comparison with cocaine. J Pharmacol Exp Ther 1989; 248: 1010-1017.
31. Fletcher PJ. Effects of d-fenfluramine and metergoline on responding for conditioned reward and the response potentiating effect of nucleus accumbens d-amphetamine. Psychopharmacology (Berlin) 1995; 118: 155-163.
32. Kuczenski R, Segal DS, Leith NJ, Applegate CD. Effects of amphetamine, methylphenidate, and apomorphine on regional brain serotonin and 5-hydroxyindole acetic acid. Psychopharmacology (Berlin) 1987; 93: 329-335.
33. Rocha BA, Goulding EH, O'Dell LE, Mead AN, Coufal NG, Parsons LH et al. Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice. J Neurosci 2002; 22: 10039-10045.
34. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999; 283: 397-401.
35. Brunner D, Buhot MC, Hen R, Hofer M. Anxiety, motor activation, and maternal-infant interactions in 5HT1B knockout mice. Behav Neurosci 1999; 113: 587-601.
36. Zhuang X, Gross C, Santarelli L, Compan V, Trillat AC, Hen R. Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors. Neuropsychopharmacology 1999; 21: 52S-60S.
37. Saudou F, Amara DA, Dierich A, LeMeur M, Ramboz S, Segu L et al. Enhanced aggressive behavior in mice lacking 5-HT1B receptor. Science 1994; 265: 1875-1878.
38. Bouwknecht JA, Hijzen TH, van der Gugten J, Maes RA, Hen R, Olivier B. Absence of 5-HT(1B) receptors is associated with impaired impulse control in male 5-HT(1B) knockout mice. Biol Psychiatry 2001; 49: 557-568.
39. Ramboz S, Saudou F, Amara DA, Belzung C, Segu L, Misslin R et al. 5-HT1B receptor knock out - behavioral consequences. Behav Brain Res 1996; 73: 305-312.
40. Compan V, Zhou M, Grailhe R, Gazzara RA, Martin R, Gingrich J et al. Attenuated response to stress and novelty and hypersensitivity to seizures in 5-HT4 receptor knock-out mice. J Neurosci 2004; 24: 412-419.
41. Brus R, Nowak P, Szkilnik R, Mikolajun U, Kostrzewa RM. Serotoninergics attenuate hyperlocomotor activity in rats. Potential new therapeutic strategy for hyperactivity. Neurotox Res 2004; 6: 317-325.
42. Boix F, Qiao SW, Kolpus T, Sagvolden T. Chronic L-deprenyl treatment alters brain monoamine levels and reduces impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder. Behav Brain Res 1998; 94: 153-162.
43. Retz W, Thome J, Blocher D, Baader M, Rosler M. Association of attention deficit hyperactivity disorder-related psychopathology and personality traits with the serotonin transporter promoter region polymorphism. Neurosci Lett 2002; 319: 133-136.
44. Zhao AL, Su LY, Zhang YH, Tang BS, Luo XR, Huang CX et al. Association analysis of serotonin transporter promoter gene polymorphism with ADHD and related symptomatology. Int J Neurosci 2005; 115: 1183-1191.
45. Comings DE, Gade-Andavolu R, Gonzalez N, Wu S, Muhleman D, Blake H et al. Comparison of the role of dopamine, serotonin, and noradrenaline genes in ADHD, ODD and conduct disorder: multivariate regression analysis of 20 genes. Clin Genet 2000; 57: 178-196.
46. Epstein J, Johnson D, Conners K. Conners Adult ADHD Diagnostic Interview for DSM-IV. Multi-Health Systems: North Tonawanda, NY, 1999.
47. Conners CK, Erhardt D, Sparrow E. Conners Adult ADHD Rating Scales. Multi-Health Systems: North Tonawanda, NY, 1999.
48. DuPaul G, Power T, Anastopoulos A, Reid R. ADHD Rating Scales, IV: Checklists, Norms, and Clinical Interpretation. Guilford Press: New York, NY, 1998.
49. Johnston HF. Attention Deficit Hyperactivity Disorder in Adults: A Guide. The Progressive Press: Rockston Ink, 2002; 52-54.
50. Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150: 885-890.
51. Sheehan D. The Anxiety Disease. Bantam: New York, NY, 1983; 138.
52. Conners CK. The computerized continuous performance test. Psychopharmacol Bull 1985; 21: 891-892.
53. Ramos JL, Cuetos F. PROLEC-SE. Evaluación de los procesos lectores en alumnos de 3er ciclo de primaria y secundaria (b), TEA ediciones, Madrid, 1999.
54. Cervera M, Toro J. Test de analisis de lectoescritura (a), TEA ediciones, Madrid, 1990.
55. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
56. Thorisson GA, Smith AV, Krishnan L, Stein LD. The International HapMap Project Web site. Genome Res 2005; 15: 1592-1593.
57. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004; 74: 106-120.
58. Sanchez JJ, Phillips C, Borsting C, Balogh K, Bogus M, Fondevila M et al. A multiplex assay with 52 single nucleotide polymorphisms for human identification. Electrophoresis 2006; 27: 1713-1724.
59. Tobler AR, Short S, Andersen MR, Paner TM, Briggs JC, Lambert SM et al. The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping. J Biomol Tech 2005; 16: 398-406.
60. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003; 19: 149-150.
61. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000; 155: 945-959.
62. Falush D, Stephens M, Pritchard JK. Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics 2003; 164: 1567-1587.
63. Goudet J. Fstat version 1.2: a computer program to calculate Fstatistics. J Hered 1995; 86: 485-486.
64. Weir BS, Cockerham CC. Estimating F-statistics for the analysis of population structure. Evolution 1984; 38: 1358-1370.
65. Pritchard JK, Rosenberg N. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999; 65: 220-228.
66. Gonzalez JR, Armengol L, Sole X, Guino E, Mercader JM, Estivill X et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007; 23: 644-645.
67. Storey JD. A direct approach to false discovery rates. J R Stat Soc, Ser B 2002; 64: 479-498.
68. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003; 25: 115-121.
69. Fallin D, Schork NJ. Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm f or unphased diploid genotype data. Am J Hum Genet 2000; 67: 947-959.
70. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-989.
71. Kirley A, Hawi Z, Daly G, McCarron M, Mullins C, Millar N et al. Dopaminergic system genes in ADHD: toward a biological hypothesis. Neuropsychopharmacology 2002; 27: 607-619.
72. Hawi Z, Foley D, Kirley A, McCarron M, Fitzgerald M, Gill M. Dopa decarboxylase gene polymorphisms and attention deficit hyperactivity disorder (ADHD): no evidence for association in the Irish population. Mol Psychiatry 2001; 6: 420-424.
73. Brookes K, Xu X, Chen W, Zhou K, Neale B, Lowe N et al. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry 2006; 11: 934-953.
74. Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Jons PH, Cohen RM. High midbrain [18F]DOPA accumulation in children with attention deficit hyperactivity disorder. Am J Psychiatry 1999; 156: 1209-1215.
75. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci 1998; 18: 5901-5907.
76. Moore BJ, Kwan SP, Bech-Hansen NT. A polymorphic dinucleotide repeat at the DXS7 locus. Nucleic Acids Res 1992; 20: 929.
77. Jiang S, Xin R, Wu X, Lin S, Qian Y, Ren D et al. Association between attention deficit hyperactivity disorder and the DXS7 locus. Am J Med Genet 2000; 96: 289-292.
78. Domschke K, Sheehan K, Lowe N, Kirley A, Mullins C, O'Sullivan R et al. Association analysis of the monoamine oxidase A and B genes with attention deficit hyperactivity disorder (ADHD) in an Irish sample: preferential transmission of the MAO-A 941G allele to affected children. Am J Med Genet B Neuropsychiatr Genet 2005; 134: 110-114.
79. Jiang S, Xin R, Lin S, Qian Y, Tang G, Wang D et al. Linkage studies between attention-deficit hyperactivity disorder and the monoamine oxidase genes. Am J Med Genet 2001; 105: 783-788.
80. Faraone SV, Biederman J, Friedman D. Validity of DSM-IV subtypes of attention-deficit/hyperactivity disorder: a family study perspective. J Am Acad Child Adolesc Psychiatry 2000; 39: 300-307.
81. Todd RD, Rasmussen ER, Neuman RJ, Reich W, Hudziak JJ, Bucholz KK et al. Familiality and heritability of subtypes of attention deficit hyperactivity disorder in a population sample of adolescent female twins. Am J Psychiatry 2001; 158: 1891-1898.
82. Rasmussen ER, Neuman RJ, Heath AC, Levy F, Hay DA, Todd RD. Familial clustering of latent class and DSM-IV defined attention-deficit/ hyperactivity disorder (ADHD) subtypes. J Child Psychol Psychiatry 2004; 45: 589-598.
83. Stawicki JA, Nigg JT, von Eye A. Family psychiatric history evidence on the nosological relations of DSM-IV ADHD combined and inattentive subtypes: new data and meta-analysis. J Child Psychol Psychiatry 2006; 47: 935-945.
84. Smoller JW, Biederman J, Arbeitman L, Doyle AE, Fagerness J, Perlis RH et al. Association between the 5HT1B receptor gene (HTR1B) and the inattentive subtype of ADHD. Biol Psychiatry 2006; 59: 460-467.
85. Waldman ID, Rowe DC, Abramowitz A, Kozel ST, Mohr JH, Sherman SL et al. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am J Hum Genet 1998; 63: 1767-1776.
86. Shih JC, Thompson RF. Monoamine oxidase in neuropsychiatry and behavior. Am J Hum Genet 1999; 65: 593-598.
87. O'Neill MF, Heron-Maxwell CL, Shaw G. 5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB. Pharmacol Biochem Behav 1999; 63: 237-243.
88. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153: 466-476.
89. Barr AM, Lehmann-Masten V, Paulus M, Gainetdinov RR, Caron MG, Geyer MA. The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. Neuropsychopharmacology 2004; 29: 221-228.